Get the Daily Brief
Latest Biotech News
Oral PCSK9 Inhibitors Demonstrate Efficacy in Late-Stage Trials
Merck & Co. reported positive results from two Phase III trials of their oral PCSK9 inhibitor enlicitide decanoate, achieving statistically significant reductions in LDL cholesterol in patients...
FDA Approves Competing RSV Antibody Drugs Amid Advisory Committee Overhaul
Merck's RSV antibody drug Enflonsia has received FDA approval for infants under 12 months, entering a market dominated by Sanofi and AstraZeneca's Beyfortus. This approval coincides with the...